The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
Maha S Al-Keilani,1 Karem H Alzoubi,1 Saied A Jaradat2,3 1Department of Clinical Pharmacy, College of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid 22110, Jordan; 3P...
Guardado en:
Autores principales: | Al-Keilani MS, Alzoubi KH, Jaradat SA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6d17358580134186b50e93e8fd057d06 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani MS, et al.
Publicado: (2018) -
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Bingyi Zhou, et al.
Publicado: (2021) -
Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy
por: Ma Y, et al.
Publicado: (2019) -
Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
por: Jacob King, et al.
Publicado: (2021) -
Molecular cloning and subcellular localization of six HDACs and their roles in response to salt and drought stress in kenaf (Hibiscus cannabinus L.)
por: Wei,Fan, et al.
Publicado: (2019)